drugset / Trial / NCT06553352
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Phase 2
Recruiting
39 enrolled
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital · collabHuazhong University of Science and Technology · collabJiangxi Provincial Cancer Hospital · collabShanxi Province Cancer Hospital · collabSun Yat-sen University · collabThe First Hospital of Jilin University · collabThe Second Affiliated Hospital of Dalian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.
Timeline
- Start
- 2024-03-31
- Primary completion
- 2026-04-20
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |